Previous 10 | Next 10 |
The following slide deck was published by CytomX Therapeutics, Inc. in conjunction with this event. For further details see: CytomX Therapeutics (CTMX) Investor Presentation - Slideshow
CytomX Therapeutics, Inc. (CTMX) Q2 2021 Earnings Conference Call August 5, 2021 05:00 PM ET Company Participants Chau Cheng - Vice President Investor Relations & Corporate Communications Sean McCarthy - President, Chief Executive Officer & Chairman Amy Peterson - Chief Development Of...
Image source: The Motley Fool. CytomX Therapeutics, inc (NASDAQ: CTMX) Q2 2021 Earnings Call Aug 6, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: CytomX Therapeutics, inc (CTMX) Q2 2021 Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platfor...
-Translational whole-body PET clinical imaging supports conditional activation in the tumor microenvironment- -Pacmilimab demonstrated single-agent activity in advanced solid tumors, including metastatic triple-negative breast cancer- -Combination of pacmilimab and ipili...
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technolog...
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody ® technology pl...
SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody ® technology pl...
Today, we revisit CytomX Therapeutics for our first in-depth look at this small oncology name since August of 2019. The company is well funded at the moment, has strategic partnerships and a few 'shots on goal'. A full investment analysis and recommendation follows in the paragrap...
Gainers: Organovo (ONVO) +24%, Iterum Therapeutics (ITRM) +16%, Adagene (ADAG) +14%, Freeline Therapeutics (FRLN) +12%, 180 Life Sciences (ATNF) +12%.Losers: Provention Bio (PRVB) -22%, Eton Pharmaceuticals (ETON) -13%, Lannett (LCI) -12%...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...